A common path through fragmented practice
Personalized phage therapy tailors viruses that selectively infect disease-causing bacteria to an individual patient. The new consensus guideline offers more than 60 recommendations spanning phage selection, pharmacy preparation, quality control, administration and monitoring. Alongside 20 professional societies, patient representatives, regulators and 18 international experts defined the same pathway.[1]
The clinical value of that common path is visibility: how a patient’s product was selected, prepared and monitored can be inspected. When centres document the same quality and safety steps, outcomes become comparable and unexpected harms are less likely to disappear among scattered case reports.[1]
Consensus cannot substitute for efficacy evidence
The evidence base consists largely of preclinical studies, early-phase trials, expert opinion and case series. That is why the document cannot specify some quality thresholds or doses across administration routes. Consensus organizes current practice; by itself it does not answer which patients benefit, or by how much.[1]
For patient care, the threshold is clear: standardized preparation must not be mistaken for proof of benefit. A useful guideline creates the ground for stronger comparisons by tracking infection type, phage product, dose, accompanying treatment, adverse events and outcome in a consistent way. The honest message to patients is equally clear: the pathway is better defined, while treatment effect still has to be measured for each use.[1]